Full-Time

Vice President

Scribe Therapeutics

Scribe Therapeutics

51-200 employees

Develops CRISPR-based genetic medicines using advanced technologies

Biotechnology

Senior, Expert

Alameda, CA, USA

Requirements
  • Advanced knowledge of drug discovery and development to advise Program Leads in designing, executing and interpreting experiments in compliance with appropriate global regulatory guidance
  • Doctorate (Ph.D.) + >15yrs experience in drug discovery (i.e. target identification and validation, drug candidate screening and nomination of drug development candidates for initiation of pharmacology and/or toxicology studies
  • Experience with the preparation of regulatory submissions (IND/CTDs, NDA/BLA, etc.) and communicating/interacting with health authorities desirable
  • Experience in the design, conduct, and interpretation of GLP or non-GLP non clinical in vitro studies
  • Experience in the development and characterization of specialty in vivo pharmacology models to generate proof-of-concept data supporting nomination of drug candidates
  • Outstanding mentoring and leadership ability
Responsibilities
  • Lead the discovery research teams and strategy to successfully bring programs from target identification and validation through lead optimization and to the clinic; be a key leader in prioritization of programs targeting a variety of genetic targets
  • Refine therapeutic workstreams and candidate evaluation strategies across integrated teams from early-stage discovery to IND
  • Establish a roadmap and build capabilities to achieve balanced infrastructure leveraging both internal expertise and external resources and drive internal and external execution of research programs, including leveraging CROs
  • Provide key insights and oversight of early target prioritization cross team functionalization and disease/indication expansion
  • Promote strong scientific excellence and foster an open culture of ideation, innovation, and deep scientific rigor
  • Contribute to deliver and present key data packages and data-driven scientific updates to the organization that impact pipeline milestones including Study Report sections, regulatory submissions, internal and external scientific updates such as abstracts/manuscripts for publication
  • Lead the expansion of the Drug Discovery team, recruiting key talent and managing, developing, and mentoring team members providing clear scientific guidance and accountability to the team to continue their growth
  • Define overall strategies for highly innovative drug discovery programs from target ID to hit identification, lead selection, and candidate nomination
  • Build cross-functional projects teams and develop project team leaders that work across disciplines, including Research, Discovery, Translational Groups, and CMC
  • Work closely with our Research groups to convert new science into new targets and advance drug discovery programs
  • Responsible for departmental administration; including budget with cost of experiments, technology, and external collaborations
Desired Qualifications
  • Familiarity with CRISPR technologies and therapeutic approaches is strongly desired
  • Familiarity with protein or RNA structure and engineering approaches

Scribe Therapeutics stands out in the field of genetic medicine with its proprietary CRISPR by Design™ approach, which is touted as the most advanced platform for CRISPR-based genetic medicine. The company's integrated technologies are specifically designed for therapeutic use, offering key advantages such as novel viral and non-viral delivery technologies for in vivo genetic medicine, and highly active editing activities capable of targeting and eliminating the root causes of diseases. Moreover, Scribe's commitment to exceptional specificity within the genome ensures therapeutic precision and allele-specific targeting, setting a high bar for industry standards.

Company Stage

Series B

Total Funding

$140.2M

Headquarters

Alameda, California

Founded

2017

Growth & Insights
Headcount

6 month growth

8%

1 year growth

37%

2 year growth

130%
INACTIVE